PathAI is focused on transforming pathology and diagnostics through innovative digital solutions. By combining advanced machine learning with deep pathology expertise, PathAI’s solutions accelerate biomarker discovery, drug development, improve patient outcomes, and support data-driven decision-making at every stage of clinical and diagnostic workflows. Together, we are redefining the future of pathology, enabling pathologists and scientists to lead the charge in modern healthcare. For more information, visit http://pathai.com/

Personalis, Inc. is a leader in advanced cancer genomics for enabling the next generation of precision cancer therapies and diagnostics. The Personalis NeXT PlatformTM is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. In population sequencing, Personalis operates one of the largest sequencing laboratories globally and is currently the sole sequencing provider to the VA MVP. To enable cancer and population sequencing, the Personalis Clinical Laboratory is built with a focus on clinical accuracy, quality, big data, scale, and efficiency. The laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).

Presage’s mission is understanding the complexity of drug response in the tumor microenvironment. Our CIVO® platform delivers trackable microdoses of multiple drugs and drug combinations directly into intact patient tumors to generate deep, spatial biology insights. CIVO’s unique approach to oncology clinical investigation informs and de-risks oncology drug development.

RefleXion transforms radiopharmaceuticals from diagnosing cancer to actively guiding delivery of external-beam radiotherapy by leveraging individual tumor biology. Designated an FDA Breakthrough Device, RefleXion’s SCINTIX biology-guided radiotherapy automates targeting and motion management to overcome long-standing barriers preventing definitive radiotherapy for metastatic disease. In strategic collaborations with radiopharmaceutical companies, RefleXion is co-developing and co-commercializing disease-specific radiotracers for difficult to treat late-stage cancers. To learn more, please visit www.reflexion.com

Rho is a global, privately held CRO headquartered in Research Triangle Park, NC and provides a full range of drug development services. For 39 years, Rho has been a trusted partner to some of the most innovative pharmaceutical and biotechnology companies, maximizing ROI by delivering consistent and efficient programs.
Experience, Rho. To learn more, please visit www.rhoworld.com

SIRPant Immunotherapeutics utilizes specifically engineered autologous macrophages (SIRPant-M) to generate polyclonal T cell and antibody responses in vivo that are tumor neo-antigen directed. Phase I trials for treatment of NHL initiate in Q4 2023, with an additional IND for treatment of solid tumors submitted Nov 2023. To learn more, please visit www.sirpantimmunotx.com.

Veracyte is a pioneering, global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions. Our growing menu of advanced diagnostic tests help patients avoid risky, costly procedures and interventions, and accelerate time to appropriate treatment. Veracyte offers customized multi-omics tools and expertise to our biopharmaceutical partners, helping them advance their therapeutic discovery, development and commercialization programs. To learn more, please visit www.veracyte.com

WorldCare Clinical is an imaging core lab originally founded in 1992 out of MGH Department of Radiology. Over the past 30 years, we have evolved as an independent company with experience with 12,000+ sites in 70+ countries and have performed services on more than 500 clinical trials.

One of the largest CDMO in Europe, Yposkesi offers a full range of services in Lentiviral vectors and AAV cGMP manufacturing. Within its 50,000 ft2 (soon to be 100,000 ft2) facility, Yposkesi operates 4 manufacturing suites for bulk DS (up to 1,000 L) and fill & finish. To learn more, please visit www.yposkesi.com

Deka’s mission is to deliver life-changing medicines to patients with cancer and inflammatory diseases by developing novel cytokine therapies.

Deka Biosciences is a venture-backed, clinical-stage biotech company focused on developing novel cytokine therapies to treat cancer and inflammatory diseases such as Crohn’s, psoriasis, rheumatoid arthritis, and sepsis. The company is led by experienced biopharma and former CDMO entrepreneurs with expertise in drug discovery, product development, characterization, and testing. Deka has developed disease specific Diakines™ that maximize patient benefits through improved pharmacokinetics / pharmacodynamics (PK/PD) function via targeted delivery of dual and complimentary cytokines to affected tissues or cells. Through the use of precision medicine, Deka’s vision is to maximize the impact of its DiakineTM therapeutic proteins by ensuring treatment of the correct patient population.